Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours Β· Estimated delivery Aug 27 - Sep 1
DAVID KESSLER: Thanks for having me
Anyone experiencing: Persistent muscle or joint pain
Half-Life and Dosing: The "half-life" of a drug is how long it takes for half of it to leave your system
Ridker PM, Macfadyen JG, Glynn RJ et al (2018) Inhibition of interleukin-1 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease
What we're seeing across the trials: Reduced cardiovascular mortality Decreased stroke risk Lower heart failure hospitalisation rates Here's what matters most: These benefits go BEYOND what we'd expect from weight loss or glycaemic control alone
US$ 23.75
US$ 23.28
US$ 22.43
US$ 29.55
US$ 24.98
US$ 23.35
US$ 29.89
